Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02569242 · ClinicalTrials.gov registry record · Phase 3
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
A Phase 3 study, sponsored by Ono Pharmaceutical Co..
- Completed
- Registry status
- Phase 3
- Development phase
- 419
- Enrollment target
NCT02569242 is a Phase 3 study that has completed, run by Ono Pharmaceutical Co.. The registered enrollment target is 419 participants.
The verdict
NCT02569242, a Phase 3 study, has completed, sponsored by Ono Pharmaceutical Co..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 419 participants
- Enrollment target
Study Summary
The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
Interventions
- DRUG Nivolumab
- DRUG Docetaxel/Paclitaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 419 participants |
| Start Date | 2015-12-14 |
| Est. Completion | 2020-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02569242
The ClinicalTrials.gov registry entry for NCT02569242 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 419 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ono Pharmaceutical Co., which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02569242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02569242 about?
NCT02569242 is a clinical study titled "Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer". The purpose of study is to evaluate the efficacy and safety of Nivolumab in unresectable advanced or recurrent esophageal cancer patients who have failed in standard chemotherapies.
What is the current status of trial NCT02569242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 419 participants. The study started on 2015-12-14. Estimated completion is 2020-10-23.
What interventions are being tested in trial NCT02569242?
The interventions under investigation include: Nivolumab (DRUG), Docetaxel/Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT02569242?
This trial is sponsored by Ono Pharmaceutical Co., which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.